Skip to main content
. Author manuscript; available in PMC: 2015 Jul 8.
Published in final edited form as: Oncogene. 2013 Dec 23;34(2):209–216. doi: 10.1038/onc.2013.543

Figure 2. Cancer cells with TRAF2 amplification depend on TRAF2 for proliferation.

Figure 2

(A) Proliferation of cells harboring (red) and lacking (blue) TRAF2 copy number gain after transduction with two distinct TRAF2-specific shRNA (shTRAF2#1 and shTRAF#2). Proliferation was normalized to cells expressing control shRNA (shLacZ). Results reported as mean ± SD of three experiments. * p<= 0.02 as calculated by a standard t test (B) Long-term proliferative capacity of cell lines following TRAF2 suppression. Population doubling (PD) of cells harboring (KYSE30, RKO, SUM52, KYSE50, and H2009) and lacking (A2780) TRAF2 copy number gain after transduction with control shRNA (shLACZ), shTRAF2#1, or shTRAF2#2. Cells were assayed for 21d. * p<= 0.04 as calculated by a standard t test.